Quick Answer
Definium Therapeutics, Inc. reported Total Assets of $440.10 million for the year ending 2025.
- Definium Therapeutics, Inc. showed an increase of +45.7% in Total Assets from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $149.23 million | Q2 2022: $134.28 million | Q3 2022: $180.91 million | Q1 2023: $155.53 million | Q2 2023: $142.09 million | Q3 2023: $141.55 million | Q1 2024: $275.53 million | Q2 2024: $268.15 million | Q3 2024: $319.77 million | Q1 2025: $275.32 million | Q2 2025: $265.09 million | Q3 2025: $236.92 million.
- Over the full 6 years of available data (2020 to 2025), Definium Therapeutics, Inc.'s Total Assets has grown by 439.9%.
- Historical annual values: Fiscal year 2025: $440.10 million | Fiscal year 2024: $302.15 million | Fiscal year 2023: $124.54 million | Fiscal year 2022: $169.99 million | Fiscal year 2021: $164.00 million | Fiscal year 2020: $81.52 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: